Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 72, Issue 18, Pages 3489-3506Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00018-015-1937-8
Keywords
Glutamate transporters; Astrocytes; Neurodegenerative disease; Glutamic acid; GLT-1; Depression; Ceftriaxone; LDN/OSU-0212320
Categories
Funding
- US National Institutes of Health [R01NS064275, U01NS074601]
- BrightFocus Foundation
- Alzheimer's Drug Discovery Foundation
- Thome Memorial Foundation
Ask authors/readers for more resources
Glutamate is the predominant excitatory neurotransmitter in the central nervous system. Excitatory amino acid transporter 2 (EAAT2) is primarily responsible for clearance of extracellular glutamate to prevent neuronal excitotoxicity and hyperexcitability. EAAT2 plays a critical role in regulation of synaptic activity and plasticity. In addition, EAAT2 has been implicated in the pathogenesis of many central nervous system disorders. In this review, we summarize current understanding of EAAT2, including structure, pharmacology, physiology, and functions, as well as disease relevancy, such as in stroke, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, Alzheimer's disease, major depressive disorder, and addiction. A large number of studies have demonstrated that up-regulation of EAAT2 protein provides significant beneficial effects in many disease models suggesting EAAT2 activation is a promising therapeutic approach. Several EAAT2 activators have been identified. Further understanding of EAAT2 regulatory mechanisms could improve development of drug-like compounds that spatiotemporally regulate EAAT2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available